What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-05-14 compared with 2020-10-23 · 19 added, 42 removed, 27 unchanged (69% of the section changed)

OTHER INFORMATION.

Copies of the following

documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

on Demand™

Sales Agreement, dated August 7, 2020, by and between Actinium Pharmaceuticals,

and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit

1.2 to Registration Statement on Form S-3 filed on August 7, 2020).

of Incorporation of Actinium Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K

filed with the SEC on April 17, 2013).

of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5

to Form S-1 filed on January 31, 2014).

of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014 (incorporated by reference to Exhibit 3.1

to Form 8-K filed on February 7, 2014).

of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit

3.1 to Form 8-K filed on March 4, 2015).

of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit

3.1 to Form 8-K filed on February 26, 2018).

of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7

to Form 10-K filed on March 15, 2019).

of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 4.1

to Form 8-K filed on June 16, 2020).

of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1

to Form 8-K filed on August 14, 2020).

to Warrant to Purchase Common Stock of Actinium Pharmaceuticals, Inc., dated March 14,

2017, issued to Sandesh Seth (incorporated by reference to Exhibit 10.2 to Form 10-K

filed on August 14, 2020).

Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc.

Seth (incorporated by reference to Exhibit 10.3 to Form 10-Q filed on August 14, 2020).

Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc.

O’Loughlin (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on August

Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc.

and Dale Ludwig (incorporated by reference

to Exhibit 10.5 to Form 10-Q filed on August 14, 2020).

Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc.

Berger (incorporated by reference to Exhibit 10.6 to Form 10-Q filed on August 14, 2020).

Copies of the following documents

are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

Title of Document

Certificate of Incorporation of Actinium Pharmaceuticals, Inc.

(incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 17, 2013).

Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).

Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014.

(incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).

Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).

Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).

Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).

Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).

Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).

Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).

Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).

Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of the Chief Financial Officer pursuant

to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of the Chief Executive Officer pursuant to U.S.C.

Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

Certification of the Chief Financial Officer pursuant to U.S.C.

Certification of the Principal Financial and Accounting Officer pursuant to U.S.C.

Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

10 unchanged sentences

specific reference in such filing.

a management contract or compensatory plan.

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned

thereunto duly authorized.

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto

duly authorized.

ACTINIUM PHARMACEUTICALS, INC.

October 23, 2020

/s/ Sandesh Seth

8 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information